Edwards Lifesciences Corp (NYSE: EW) Not A Good Play Anymore?

Edwards Lifesciences Corp (EW) concluded trading on Thursday at a closing price of $70.99, with 4.16 million shares of worth about $295.41 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 14.48% during that period and on February 06, 2025 the price saw a loss of about -1.54%. Currently the company’s common shares owned by public are about 589.80M shares, out of which, 579.26M shares are available for trading.

Stock saw a price change of -3.05% in past 5 days and over the past one month there was a price change of -3.47%. Year-to-date (YTD), EW shares are showing a performance of -4.11% which decreased to -17.51% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $58.93 but also hit the highest price of $96.12 during that period. The average intraday trading volume for Edwards Lifesciences Corp shares is 4.84 million. The stock is currently trading -0.08% below its 20-day simple moving average (SMA20), while that difference is down -1.82% for SMA50 and it goes to -5.72% lower than SMA200.

Edwards Lifesciences Corp (NYSE: EW) currently have 589.80M outstanding shares and institutions hold larger chunk of about 87.55% of that.

The stock has a current market capitalization of $41.87B and its 3Y-monthly beta is at 1.13. PE ratio of stock for trailing 12 months is 10.24, while it has posted earnings per share of $6.93 in the same period. Its PEG reads 3.41 and has Quick Ratio of 2.89 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EW, volatility over the week remained 1.42% while standing at 2.10% over the month.

Stock’s fiscal year EPS is expected to rise by 2.31% while it is estimated to decrease by -4.84% in next year. EPS is likely to shrink at an annualized rate of 3.00% for next 5-years, compared to annual growth of 15.35% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stifel on January 30, 2025 offering a Buy rating for the stock and assigned a target price range of between $75 and $90 to it. Coverage by Wolfe Research stated Edwards Lifesciences Corp (EW) stock as an Underperform in their note to investors on January 16, 2025, suggesting a price target of $60 for the stock. On December 16, 2024, BofA Securities Upgrade their recommendations, while on October 11, 2024, Morgan Stanley Resumed their ratings for the stock with a price target of $70. Stock get a Hold rating from Jefferies on September 18, 2024.

Most Popular

Related Posts